Trial Profile
A Phase I, Open-Label Study Evaluating the Bioavailability of ALX-0061 After Subcutaneous and Intravenous Administration in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Vobarilizumab (Primary) ; Vobarilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Ablynx
- 23 Oct 2014 Results published in an Ablynx media release.
- 21 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Apr 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.